Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy.

European journal of cancer (Oxford, England : 1990) - 1 Jan 2006

Chan S K, Gullick W J, Hill M E

Abstract excerpt

The targeting of the ATP binding pocket of the epidermal growth factor receptor (EGFR) tyrosine kinase, by the small molecule drugs gefitinib and erlotinib, represents a promising new therapeutic strategy in non-small cell lung cancer. However, it is now apparent that only a subset of patients responds to such treatment. Two publications in early 2004 reported the presence of activating mutations in the EGFR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Gefitinib
Share to EGFR gene

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genetic Therapy

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Protein-Tyrosine Kinases

Source

Identifiers

PMID: 16364841
DOI: 10.1016/j.ejca.2005.07.031

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy.PMID 16364841Read ↗

Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer.Semantic proximity Read ↗

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.Semantic proximity Read ↗

Review. EGFR mutations in non-small cell lung cancer--clinical implications.Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer.Semantic proximity Read ↗

Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer.Semantic proximity Read ↗

Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.Semantic proximity Read ↗

Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer.Semantic proximity Read ↗

Epidermal growth factor receptor mutations in non-small cell lung cancer: a basic science discovery with immediate clinical impact.Semantic proximity Read ↗

Update on epidermal growth factor receptor mutations in non-small cell lung cancer.Semantic proximity Read ↗

Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive.Semantic proximity Read ↗

Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations.Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.